Outcomes for Recurrent Mantle Cell Lymphoma Post-Ibrutinib Therapy: A Retrospective Cohort Study from a Japanese Administrative Database.

Shinya RaiYoshinori TanizawaZhihong CaiYu-Jing HuangKaisa TaipaleMasaomi Tajimi

Published in: Advances in therapy (2022)

Patients with MCL previously treated with ibrutinib have poor ability to carry out ADL and experience very poor outcomes. New safe, effective therapies are needed.

Keyphrases

chronic lymphocytic leukemia
emergency department
stem cells
adipose tissue
metabolic syndrome
adverse drug
cell therapy